Journal of stomatology, oral and maxillofacial surgery · 2026
Methoxyflurane as an analgesic and sedative agent in oral and maxillofacial surgery: a scoping review.
СтатьяScoping ReviewНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lima Bernardo Correia, Dos Santos Pedro Américo Felizardo, Coutinho Michelle Alonso, Grillo Ricardo, Brozoski Mariana Aparecida, Melhem-Elias Fernando
Аннотация
INTRODUCTION: Methoxyflurane (MOF) is a low-dose inhaled analgesic with rapid onset, patient-controlled titration, and an established safety profile at sub-anesthetic doses. Its potential role in oral and maxillofacial surgery (OMFS) has not been comprehensively mapped.
OBJECTIVE: To map and characterize available evidence on inhaled methoxyflurane in OMFS, including dento-alveolar surgery, acute oral pain emergencies, and outpatient analgesic-sedation.
METHODS: Scoping review conducted following JBI methodology and reported per PRISMA-ScR. Eligibility defined by PCC (Population, Concept, Context) framework. Searched: MEDLINE (PubMed), Embase, Cochrane CENTRAL, Scopus, and Web of Science, with no date restriction. Two independent reviewers screened records; data charted using a standardised form.
RESULTS: Twenty studies were identified: 10 with direct OMFS/dental relevance (2 RCTs, 2 case series, 1 clinical study, 2 narrative reviews, 1 systematic review, 1 feasibility review, 1 ongoing Phase 3 RCT) and 10 with indirect but clinically translatable relevance. MOF demonstrated comparable sedation and greater patient preference versus nitrous oxide in third molar surgery (p < 0.05). Systematic reviews in outpatient procedural contexts reported satisfaction rates of 63%->98% and no serious adverse events at analgesic doses. The pivotal METODO trial (NCT06495372), a Phase 3 placebo-controlled RCT in adult dental emergencies, is currently enrolling (expected completion October 2026).
CONCLUSION: Available evidence supports the clinical feasibility of MOF in OMFS, particularly for third molar surgery and acute oral pain. High-quality OMFS-specific RCTs remain lacking. The METODO trial will provide pivotal data to guide practice. Future research should address OMFS-specific protocols and jurisdictions where MOF lacks regulatory approval.
OBJECTIVE: To map and characterize available evidence on inhaled methoxyflurane in OMFS, including dento-alveolar surgery, acute oral pain emergencies, and outpatient analgesic-sedation.
METHODS: Scoping review conducted following JBI methodology and reported per PRISMA-ScR. Eligibility defined by PCC (Population, Concept, Context) framework. Searched: MEDLINE (PubMed), Embase, Cochrane CENTRAL, Scopus, and Web of Science, with no date restriction. Two independent reviewers screened records; data charted using a standardised form.
RESULTS: Twenty studies were identified: 10 with direct OMFS/dental relevance (2 RCTs, 2 case series, 1 clinical study, 2 narrative reviews, 1 systematic review, 1 feasibility review, 1 ongoing Phase 3 RCT) and 10 with indirect but clinically translatable relevance. MOF demonstrated comparable sedation and greater patient preference versus nitrous oxide in third molar surgery (p < 0.05). Systematic reviews in outpatient procedural contexts reported satisfaction rates of 63%->98% and no serious adverse events at analgesic doses. The pivotal METODO trial (NCT06495372), a Phase 3 placebo-controlled RCT in adult dental emergencies, is currently enrolling (expected completion October 2026).
CONCLUSION: Available evidence supports the clinical feasibility of MOF in OMFS, particularly for third molar surgery and acute oral pain. High-quality OMFS-specific RCTs remain lacking. The METODO trial will provide pivotal data to guide practice. Future research should address OMFS-specific protocols and jurisdictions where MOF lacks regulatory approval.